T1	Participants 212 338	Breast cancer patients with prior response to endocrine therapy achieve subsequent benefit from additional endocrine therapies
T2	Participants 446 588	post menopausal patients who had disease progression after receiving antiestrogen therapy either for metastatic disease or as adjuvant therapy
T3	Participants 642 669	683 postmenopausal patients
